IMRX
USDImmuneering Corporation Class A Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$1.470
고가
$1.490
저가
$1.430
거래량
0.01M
기업 기본 정보
시가총액
52.5M
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.20M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of
